April 3 (Reuters) - Mesoblast Ltd MSB.AX
* FDA clears heart disease trial at Harvard's Boston Children's Hospital using Mesoblast's Cell Therapy to grow heart muscle in children with congenital heart disease Source text for Eikon: ID:nGNXNSHIQa Further company coverage: MSB.AX